SAGE THERAPEUTICS, INC.

(SAGE)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
43.02 USD   +2.55%
08/03Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating
MT
08/03Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Rating
MT
08/03Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Value Index

06/24/2022 | 12:00am EDT

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Value Index


© S&P Capital IQ 2022
All news about SAGE THERAPEUTICS, INC.
08/03Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating
MT
08/03Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Ra..
MT
08/03Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Ratin..
MT
08/02TRANSCRIPT : Sage Therapeutics, Inc., Q2 2022 Earnings Call, Aug 02, 2022
CI
08/02Sage Therapeutics Widens Q2 Net Loss as Revenue Declines
MT
08/02SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
08/02Sage Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
CI
08/02SAGE THERAPEUTICS : Announces Second Quarter 2022 Financial Results and Highlights Pipelin..
PU
08/02Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeli..
BU
08/01Sage Therapeutics to Present at Upcoming August Investor Conferences
BU
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 6,91 M - -
Net income 2022 -519 M - -
Net cash 2022 1 120 M - -
P/E ratio 2022 -4,95x
Yield 2022 -
Capitalization 2 541 M 2 541 M -
EV / Sales 2022 206x
EV / Sales 2023 12,7x
Nbr of Employees 471
Free-Float 87,5%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 43,02 $
Average target price 57,81 $
Spread / Average Target 34,4%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
Amy Schacterle Senior VP-Research & Development Strategy
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.1.13%2 541
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-20.64%41 093